VANCOUVER, BC, June 24,
2024 /PRNewswire/ -- Bold Therapeutics, a
clinical-stage metallotherapeutics company, has been invited to
speak at the 2024 'Metals in Medicine' GRC held in Andover, New Hampshire between June 23 to 28, 2024. The conference program,
Fostering Collaborations to Diagnose and Treat Diseases with
Metal-Based Agents, features a variety of global speakers and
academic experts targeting the most recent advancements in the
field of metallotherapeutics to treat infectious diseases and
cancer.
Mark Bazett, PhD, Sr Director of
Preclinical Development at Bold Therapeutics, presented on
Monday, June 24th, in the session
titled: Clinical Advances for Metals in Medicine. Bazett's
talk is titled, Clinical Development of BOLD-100, a
Ruthenium-Based Therapeutic Currently in Phase 2 Studies for the
Treatment of Advanced Gastrointestinal Cancers. Dr. Bazett
presented positive Phase 2 clinical results of BOLD-100 in
colorectal, biliary tract, and gastric cancers, as well as sharing
updates on Bold Therapeutics' unique novel metallotherapeutic
screening program and development strategy. Shane Harrypersad, PhD, Sr Scientist, CMC is
also representing Bold Therapeutics at the Metals in Medicine
conference.
"Following the announcement of strongly positive Phase 2 results
at the 2024 ASCO and ASCO GI Annual Meetings earlier this year,
Bold Therapeutics' BOLD-100 is now the most advanced novel
metallotherapeutic in development," stated Dr. Bazett. "The 'Metals
in Medicine' conference represents an excellent opportunity for
industry leader Bold Therapeutics to strengthen our existing
academic collaborations as well as identify compelling new
collaborations and potential metallotherapeutic development
candidates from the top labs globally." In addition to presenting
at the conference, Bold Therapeutics will be meeting with academic
experts and key opinion leaders in the metallotherapeutic
space.
Yasmin Borutzki, BSc. MSc., a
graduate student in the Meier-Menches Lab at University of
Vienna, a close collaborator of
Bold Therapeutics, presented a poster on translational research
into BOLD-100 entitled: Of Mice and Men: Reverse Translation
Investigation of BOLD-100's Mechanism-of-Action.
For more information about Bold Therapeutics, please visit:
https://www.bold-therapeutics.com/
For more information about the Gordon Research Conference,
please visit:
https://www.grc.org/metals-in-medicine-conference/2024
Contact: E. Russell McAllister,
CEO
+1 (604) 262-9899
379550@email4pr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/positive-phase-2-and-mechanism-of-action-data-for-bold-100-presented-at-2024-metals-in-medicine-gordon-research-conference-302180416.html
SOURCE Bold Therapeutics Inc.